Praxis Precision Medicines, Inc., under the ticker name PRAX, has released updated information on the Phase 2a proof of concept study for PRAX-628 treating epilepsy patients who exhibit Photo Paroxysmal Response (PPR). Remarkably, in the cohort who received a 45mg dosage, every patient responded completely to the treatment. Similarly, in the 15mg dosage group, 80% of patients fully responded, while 20% had a partial response, as reported by the company.
Marcio Souza, the President and CEO of Praxis, commented on the outstanding response, revealing that it has expedited their future planning for the PRAX-628 efficacy study specifically for focal epilepsy. This follow-up study is scheduled to commence in the second half of 2024.
For more updates and health-related news, one can visit rttnews.com.
